EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism

Shalender Bhasin, Thomas G Travison, Karol M Pencina, Michael O'Leary, Glenn R Cunningham, A Michael Lincoff, Steven E Nissen, M Scott Lucia, Mark A Preston, Mohit Khera, Nader Khan, Michael C Snabes und 4 weitere

JAMA Network Open · 27.12.2023 · 6 (12) · e2348692

DOI: 10.1001/jamanetworkopen.2023.48692 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 27.12.2023. Verfasst von Shalender Bhasin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Ha…. Hauptthemen laut MEDLINE: Hypogonadism, Prostatic Neoplasms, Testosterone, Urinary Retention. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The effect of testosterone replacement therapy (TRT) on the risk of prostate cancer and other adverse prostate events is unknown.

Objective

To compare the effect of TRT vs placebo on the incidences of high-grade prostate cancers (Gleason score ≥4 + 3), any prostate cancer, acute urinary retention, invasive prostate procedures, and pharmacologic treatment for lower urinary tract symptoms in men with hypogonadism. Design, Setting, and Participants This placebo-controlled, double-blind randomized clinical trial enrolled 5246 men (aged 45-80 years) from 316 US trial sites who had 2 testosterone concentrations less than 300 ng/dL, hypogonadal symptoms, and cardiovascular disease (CVD) or increased CVD risk. Men with prostate-specific antigen (PSA) concentrations greater than 3.0 ng/mL and International Prostate Symptom Score (IPSS) greater than 19 were excluded. Enrollment took place between May 23, 2018, and February 1, 2022, and end-of-study visits were conducted between May 31, 2022, and January 19, 2023.

Intervention

Participants were randomized, with stratification for prior CVD, to topical 1.62% testosterone gel or placebo. Main Outcomes and Measures The primary prostate safety end point was the incidence of adjudicated high-grade prostate cancer. Secondary end points included incidence of any adjudicated prostate cancer, acute urinary retention, invasive prostate surgical procedure, prostate biopsy, and new pharmacologic treatment. Intervention effect was analyzed using a discrete-time proportional hazards model.

Results

A total of 5204 men (mean [SD] age, 63.3 [7.9] years) were analyzed. At baseline, the mean (SD) PSA concentration was 0.92 (0.67) ng/mL, and the mean (SD) IPSS was 7.1 (5.6). The mean (SD) treatment duration as 21.8 (14.2) months in the TRT group and 21.6 (14.0) months in the placebo group. During 14 304 person-years of follow-up, the incidence of high-grade prostate cancer (5 of 2596 [0.19%] in the TRT group vs 3 of 2602 [0.12%] in the placebo group; hazard ratio, 1.62; 95% CI, 0.39-6.77; P = .51) did not differ significantly between groups; the incidences of any prostate cancer, acute urinary retention, invasive surgical procedures, prostate biopsy, and new pharmacologic treatment also did not differ significantly. Change in IPSS did not differ between groups. The PSA concentrations increased more in testosterone-treated than placebo-treated men. Conclusions and Relevance In a population of middle-aged and older men with hypogonadism, carefully evaluated to exclude those at high risk of prostate cancer, the incidences of high-grade or any prostate cancer and other prostate events were low and did not differ significantly between testosterone- and placebo-treated men. The study’s findings may facilitate a more informed appraisal of the potential risks of TRT. Trial Registration ClinicalTrials.gov Identifier: NCT03518034

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypogonadismProstatic NeoplasmsTestosteroneUrinary RetentionHormone Replacement TherapyAgedHumansMaleMiddle AgedCardiovascular DiseasesProstateProstate-Specific Antigen

Substanzen

Prostate-Specific AntigenTestosterone

Autor:innen und Institutionen

  • Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Marcus Institute for Aging Research, Hebrew Senior Life, Division of Gerontology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Baylor College of Medicine, Houston, Texas.
  • Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.
  • Department of Pathology, University of Colorado, Aurora.
  • Division of Urology, Brigham and Women's Hospital, Boston, Massachusetts.

Zitieren

APA

Bhasin, S., Travison, T. G., Pencina, K. M., O'Leary, M., Cunningham, G. R., Lincoff, A. M., Nissen, S. E., Lucia, M. S., Preston, M. A., Khera, M., Khan, N., Snabes, M. C., Li, X., Tangen, C. M., Buhr, K. A., & Thompson, I. M. (2023). Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism. JAMA Network Open, 6(12), e2348692. https://doi.org/10.1001/jamanetworkopen.2023.48692

Vancouver

Bhasin S, Travison TG, Pencina KM, O'Leary M, Cunningham GR, Lincoff AM, et al. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism. JAMA Network Open. 2023;6(12):e2348692. doi:10.1001/jamanetworkopen.2023.48692

BibTeX
@article{Bhasin2023,
  author = {Bhasin, Shalender and Travison, Thomas G and Pencina, Karol M and O'Leary, Michael and Cunningham, Glenn R and Lincoff, A Michael and Nissen, Steven E and Lucia, M Scott and Preston, Mark A and Khera, Mohit and Khan, Nader and Snabes, Michael C and Li, Xue and Tangen, Catherine M and Buhr, Kevin A and Thompson, Ian M},
  title = {Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism},
  journal = {JAMA Network Open},
  year = {2023},
  volume = {6},
  number = {12},
  pages = {e2348692},
  doi = {10.1001/jamanetworkopen.2023.48692}
}
Kostenlos starten →